1 d animals, but not in the group treated with cyproheptadine.

2 gically by the serotonin receptor antagonist cyproheptadine.

3 ps: inferior MI and inferior MI treated with cyproheptadine (0.5 mg/kg/d).

4 t the hypothesis that post-MI treatment with cyproheptadine (5-HT2BR antagonist) can prevent ischemic

5 a P2Y1 receptor-selective antagonist, and/or cyproheptadine, a 5-hydroxytryptamine subtype 2A recepto

6 he nonspecific serotonin receptor antagonist cyproheptadine and the specific serotonin receptor 2 ant

7  valproate, levetiracetam, the antihistamine cyproheptadine, and the antidepressant amitriptyline.

8 ceptor antagonists (including MDL-100907 and cyproheptadine (CYP)) were found to inhibit 5-HT-induced

9                                              Cyproheptadine given after inferior MI reduces post-MI 5

10  leaflet size following MI was larger in the cyproheptadine group (+40% +/- 9% vs +22% +/- 12%; P = 0

11 % +/- 7% in the MI group vs 2% +/- 6% in the cyproheptadine group (P = 0.0001).

12 e serotonin-reuptake inhibitor) and received cyproheptadine hydrochloride on her third day of symptom

13 ese effects were reversed by the presence of cyproheptadine, indicating that 5-HT function was essent

14  weight gain, such as progestational agents, cyproheptadines, pentoxifylline, and thalidomide may wor

15 lopramide (RR = 3.11, 95% C.I. = 1.39-6.98), cyproheptadine, (RR = 2.76, 95% C.I. = 2.00-3.82), sulpi

16 hours after she received the loading dose of cyproheptadine, she was alert and oriented and at her ba

17 ents, decreasing from metoclopramide through cyproheptadine, sulpiride, propantheline, diphenhydramin

18             The 5-HT(2) receptor antagonist, cyproheptadine, was then administered to determine wheth

19 e and the 5-HT serotonin receptor antagonist cyproheptadine were conducted.